Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.31 (
beta-glucuronidase
)
7,680
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The purposes of this study were to develop a HPLC method to assay for haloperidol glucuronide (HALG); to apply this assay method to the in vitro determination of haloperidol (HAL) UDP-glucuronosyltransferase (UGT) enzyme kinetics in rat liver microsomes (RLM); and to identify the UGT isoforms catalyzing glucuronidation of HAL in rats. Incubation of Brij-activated RLM with HAL and UDP-glucuronic acid (UDPGA) in
TRIS
pH 7.4 buffer resulted in the formation of a single peak in the HPLC chromatogram at 270 nm. The identity of this peak was confirmed to be that of HALG by 1)
beta-glucuronidase
hydrolysis; 2) incubation without UDPGA; 3) UV spectral analysis; and 4) LC/MS/MS to yield the expected mass of 552.1. Enzyme kinetic studies using single enzyme Michaelis-Menton model showed an apparent Vmax = 271.9 +/- 10.1 pmoles min(-1) mg protein(-1) and Km = 61 +/- 7.2 microM. Glucuronidation activity in homozygous Gunn (j/j) rats was approximately 80% as compared to Sprague-Dawley RLM. HALG formation was approximately doubled in PB-induced RLM. There was no increase in glucuronidation activities in 3MC-induced RLM. The Gunn rat and the PB-induced RLM data suggest predominant but not exclusive involvement of the UGT2B family in the formation of HALG. Because the UGTs exhibit overlapping substrate specificities and most substrates are glucuronidated by more than one isoform, inhibition studies with UGT2B1 substrate probe testosterone and the UGT2B12 substrate probe borneol were conducted. UGT2B1 and UGT2B12 exhibited 40% and 90% inhibition of HAL glucuronidation, respectively. Thus, UGT2B12 and UGT 2B1 isoforms are responsible for catalyzing HAL glucuronidation in rats. Our HPLC assay provides a specific and sensitive technique for the measurement of in vitro HAL-UGT activity.
...
PMID:Glucuronidation of haloperidol by rat liver microsomes: involvement of family 2 UDP-glucuronosyltransferases. 1501 Feb 63
This study reports the development of a specific and sensitive liquid chromatography coupled with tandem mass spectrometry detection (LC-MS/MS) assay for the quantification of the in vitro O-glucuronidation of chloramphenicol (CP), the determination of the kinetic parameters for the O-glucuronidation of CP in pooled human liver microsomes (HLM), the biosynthesis of the CP glucuronides (CPGlu), and identification of the structures of CPGlu by (1)H-nuclear magnetic resonance (NMR) and MS. Two glucuronyl derived metabolites of CP were obtained from the incubation of alamethicin-activated HLM with CP and uridine 5'-diphosphoglucuronic acid (UDPGA) in pH 7.4
TRIS
buffer. Their identification and structural confirmation were achieved by
beta-glucuronidase
hydrolysis, in the presence and absence of UDPGA, and by (1)H-NMR and LC-MS/MS. These two metabolites were biosynthesized, isolated, and purified using high-performance liquid chromatography (HPLC). Their structures were further identified as the 1-O-CPGlu (the minor glucuronide formed at the secondary alcohol of CP) and 3-O-CPGlu (the major glucuronide formed at the primary alcohol of CP) by LC-MS/MS and two-dimensional NMR. The enzymatic kinetic parameters K(m) and V(max) in HLM for the 3-O-CPGlu were determined to be 650 microM and 0.26 nmoles min(-1) mg(-1), respectively, and for the 1-O-CPGlu to be 301 microM and 0.014 nmoles min(-1) mg(-1), respectively. This study also provides a sensitive and specific method for the measurement of in vitro CP-UDP-glucuronosyltransferase (UGT) activity.
...
PMID:Identification and characterization of two chloramphenicol glucuronides from the in vitro glucuronidation of chloramphenicol in human liver microsomes. 1789 23